← Back to Search

Unknown

KM-819 for Parkinson's Disease

Phase 2
Waitlist Available
Research Sponsored by FAScinate Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up part 1a and part 1b: from screening (day -42 to -3) up to 7 days and part 2: from screening (day -42 to -2) to 730 days

Summary

This trial is testing KM-819, a new drug, to see if it can stop or slow down Parkinson's disease. It involves healthy older adults and people with Parkinson's disease. Researchers aim to find out if KM-819 is safe and can improve symptoms and daily function in these patients.

Who is the study for?
This trial is for healthy adults and those with Parkinson's disease (PD) who are stable on PD medications for at least 8 weeks. Participants should be in early to moderate stages of PD, not have other neurodegenerative disorders or significant cognitive decline, and must agree to use effective contraception.
What is being tested?
The study tests KM-819's ability to slow down or stop the progression of Parkinson's disease. It compares the effects of different doses of KM-819 against a placebo in both healthy participants and those with PD.
What are the potential side effects?
While specific side effects aren't listed, typical ones may include nausea, headache, dizziness, or allergic reactions. The study aims to determine how well participants tolerate KM-819 and will monitor any adverse reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~part 1a and part 1b: from screening (day -42 to -3) up to 7 days and part 2: from screening (day -42 to -2) to 730 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and part 1a and part 1b: from screening (day -42 to -3) up to 7 days and part 2: from screening (day -42 to -2) to 730 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part 1a,1b and 2: Number of participants with adverse events and serious adverse events
Part 2: Change from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II: Activities of Daily Living (ADL) Score at Day 730
Secondary study objectives
Part 1a and 1b: AUC from pre-dose (time zero) extrapolated to time infinity [AUC(0-inf)]
Part 1a and 1b: AUC from pre-dose (time zero) to 24 hours post-dose [AUC(0-24)]
Part 1a and 1b: AUC normalized to dose administered (AUC_D)
+25 more
Other study objectives
Digital biomarkers using the Parkinson's Disease Digital Biomarker Solutions from Roche Molecular Solutions.

Trial Design

8Treatment groups
Experimental Treatment
Group I: Part 2: Cohort 2.2 Dose YExperimental Treatment2 Interventions
Participants with Parkinson's disease will receive oral doses of KM-819 (dose to be determined based on the findings from Part 1) or matching placebo once-daily for 730 days and will be allowed to take study intervention with or without fasting.
Group II: Part 2: Cohort 2.1 Dose XExperimental Treatment2 Interventions
Participants with Parkinson's disease will receive oral doses of KM-819 (dose to be determined based on the findings from Part 1) or matching placebo once-daily for 730 days and will be allowed to take study intervention with or without fasting.
Group III: Part 1b: Cohort 1.3b Dose 600 mgExperimental Treatment2 Interventions
Participants with Parkinson's disease will receive oral 600 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
Group IV: Part 1b: Cohort 1.2b Dose 400 mgExperimental Treatment2 Interventions
Participants with Parkinson's disease will receive oral 400 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
Group V: Part 1b: Cohort 1.1b Dose 200 mgExperimental Treatment2 Interventions
Participants with Parkinson's disease will receive oral 200 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
Group VI: Part 1a: Cohort 1.3a Dose 800 mgExperimental Treatment2 Interventions
Healthy older adult participants will receive oral 800 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
Group VII: Part 1a: Cohort 1.2a Dose 600 mgExperimental Treatment2 Interventions
Healthy older adult participants will receive oral 600 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
Group VIII: Part 1a: Cohort 1.1a Dose 400 mgExperimental Treatment2 Interventions
Healthy older adult participants will receive oral 400 mg dose of KM-819 or matching placebo once-daily for 7 days, after fasting for 2 hours prior to administration of study intervention and will be required to fast for 1 hour after administration of study intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
KM-819
2016
Completed Phase 1
~90
Placebo
1995
Completed Phase 3
~2670

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Parkinson's Disease (PD) primarily focus on dopaminergic therapies, which aim to replenish or mimic dopamine, a neurotransmitter that is deficient in PD. Levodopa, often combined with carbidopa, is the most potent and directly converts to dopamine in the brain. Dopamine agonists (e.g., pramipexole, ropinirole) stimulate dopamine receptors, while MAO-B inhibitors (e.g., rasagiline, selegiline) prevent the breakdown of dopamine. These treatments alleviate symptoms but do not halt disease progression. Neuroprotective strategies, like those being studied with KM-819, aim to slow or stop neurodegeneration by targeting pathways involved in neuronal survival and reducing inflammation. This approach is crucial as it addresses the underlying disease mechanisms, potentially preserving neuronal function and improving long-term outcomes for PD patients.
Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.Advances in drug development for Parkinson's disease: present status.

Find a Location

Who is running the clinical trial?

FAScinate Therapeutics Inc.Lead Sponsor
ParexelIndustry Sponsor
313 Previous Clinical Trials
96,370 Total Patients Enrolled

Media Library

KM-819 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05670782 — Phase 2
Parkinson's Disease Research Study Groups: Part 1a: Cohort 1.1a Dose 400 mg, Part 1a: Cohort 1.2a Dose 600 mg, Part 1a: Cohort 1.3a Dose 800 mg, Part 1b: Cohort 1.1b Dose 200 mg, Part 1b: Cohort 1.2b Dose 400 mg, Part 1b: Cohort 1.3b Dose 600 mg, Part 2: Cohort 2.1 Dose X, Part 2: Cohort 2.2 Dose Y
Parkinson's Disease Clinical Trial 2023: KM-819 Highlights & Side Effects. Trial Name: NCT05670782 — Phase 2
KM-819 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05670782 — Phase 2
~81 spots leftby Oct 2025